title: Novel biomarker platforms in toxicology.
abstract: About 75% of the costs of developing new drugs are expended on unsuccessful compounds and, in spite of billions spent on toxicity and other testing, post-launch withdrawal of compounds owing to toxicity still occurs. Novel biomarkers are seen as a means of reducing this expenditure by enabling better decision making. This article will review the value of some of these biomarkers and barriers to their introduction.:
authors: Biotrin International, 93 The Rise, Mount Merrion, Co Dublin, Ireland. Electronic address:Martin.shaw@biotrin.ie.
authors: Martin
authors: M
authors: Shaw